Presidio Property Trust, Inc. (SQFT) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Presidio Property Trust, Inc. is an internally-managed REIT holding a portfolio of office, industrial, retail, and model home properties. The company is classified as a non-accelerated filer and a smaller reporting company. As of the reporting date, the company owned 75 model homes and 9 commercial properties across several states, including Colorado, North Dakota, California, Texas, and Maryland.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $3.77 million | $4.13 million |
| Net Income (Consolidated) | $0.56 million | $2.38 million |
| Net Loss (Common Stockholders) | $(0.13) million | $1.69 million |
| Net Cash Used in Operating Activities | $(0.96) million | $(0.12) million |
| Net Cash Provided by Investing Activities | $6.89 million | $13.55 million |
| Net Cash Used in Financing Activities | $(8.18) million | $(9.51) million |
| Cash and Restricted Cash | $5.17 million | $11.96 million |
| Total Mortgage Debt (Principal) | $82.41 million | $92.92 million |
| Total Assets | $111.25 million | $122.05 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 8.5% year-over-year, primarily due to the sale of the Dakota Center commercial property in January 2026, which reduced rental income.
- Profitability Shift: While consolidated net income was positive ($0.56 million), it was driven by a $3.42 million gain on the disposition of assets and liabilities (Dakota Center). Excluding this gain, the company reported a net loss attributable to common stockholders of $0.13 million, compared to a net income of $1.69 million in Q1 2025.
- Impairment Charges: Non-cash impairment charges increased significantly to $0.52 million in Q1 2026 from $0.03 million in Q1 2025. Approximately $0.4 million of this was related to the Shea Center II property.
- Debt Reduction: Total mortgage debt decreased by approximately $10.5 million, largely due to the payoff of the Dakota Center loan upon its sale.
- Dividend Suspension: The Board suspended monthly dividends on Series D Preferred Stock effective January 2026. As of March 31, 2026, cumulative preferred dividends in arrears totaled approximately $0.6 million.
Guidance, Outlook, and Risks
- Shea Center II Default: The company failed to repay the Shea Center II loan by its January 5, 2026 maturity. The property was placed into receivership on February 13, 2026, with a foreclosure sale scheduled for June 17, 2026. The lender holds approximately $2.4 million in restricted cash.
- Liquidity: Management believes existing cash, cash flows from operations, and proceeds from property sales will fund operations for at least the next 12 months. However, the company is actively seeking to reduce General and Administrative (G&A) expenses, including a voluntary 5% salary reduction for the CEO and a reduction in Board size.
- Dividend Policy: No dividends were declared on Series A Common Stock or Series D Preferred Stock for Q1 2026. The company intends to reassess dividend payments quarterly based on cash availability.
- Strategic Committee: A Strategic Planning and Cyber Committee was established in June 2024 to oversee business strategy and cybersecurity risks, though no specific strategic alternatives have been disclosed.
Investor Verification Checklist
- Shea Center II Foreclosure: Verify the outcome of the June 17, 2026 foreclosure auction and the potential impact on the company's balance sheet and cash reserves.
- Dividend Arrears: Monitor the accumulation of Series D Preferred Stock dividends in arrears and the conditions required for their reinstatement.
- Model Home Concentration: Review the concentration risk regarding model home tenants, as one homebuilder accounted for approximately 17.17% of total revenue and 52 of 75 model home leases.
- Debt Maturities: Confirm the schedule for remaining debt maturities, particularly the $20.4 million in principal payments due in the remainder of 2026.
- Conduit Pharmaceuticals Investment: Track the fair value of the remaining warrants and securities in Conduit Pharmaceuticals, which totaled approximately $5,885 as of March 31, 2026.